

# Is there a role for FLASH in particle radiotherapy?

W. Tinganelli

Preclinical Radiobiology Group, Biophysics Department

GSI Helmholtzzentrum für Schwerionenforschung GmbH, Darmstadt, Germany

**HITRIplus project meeting and Hadrontherapy Workshop**

**Podgorica, Montenegro. 25th March 2025**

# FLASH RT: what's that?

Table 1. Comparison of characteristics of FLASH-RT and CONV-RT.


	FLASH-RT	CONV-RT
<b>Mean dose rate</b>	$\geq 40$ Gy/s	$\leq 1$ Gy/min
<b>Delivery time</b>	<200 ms	> 1 min
<b>Dose delivery</b>	High dose in a single fraction	Low dose in a single fraction
<b>Tumor control</b>	A similar antitumor effect as CONV-RT	Effective tumor killing
<b>Normal tissue sparing</b>	Reduce the damage to healthy tissues	Acute and late damage to healthy tissues
<b>Defects</b>	Few accessible irradiation facilities	Radiation injury and limited treatment window

FLASH-radiotherapy (FLASH-RT), Conventional dose rate radiotherapy (CONV-RT).

Mini-review

FLASH radiotherapy: A new milestone in the field of cancer radiotherapy

Rui Tang <sup>a,b,1</sup>, Jianqiong Yin <sup>b,1</sup>, Yuanxin Liu <sup>b,1</sup>, Jianxin Xue <sup>b,c,d,e,2</sup> ✉



Vozenin, Bourhis & Durante, *Nat. Rev. Clin. Oncol.* 2022

# FLASH Effect hypothesis

The FLASH effect might stem from the **rapid generation of free radicals** and distinctions in redox and free radical chemistry between normal and tumor tissues;

R. Labarbe, et al. *Radiother. Oncol.* **153**, 303–310 (2020).

Irradiation at UHDR might partially **deplete oxygen** in the tissues;

R. Abolfath, et al. *Med. Phys.* **47**, 6551–6561 (2020).

Biological factors like changes in the **immune system response to radiation or altered signaling pathways** within cells exposed to UHDR;

J. Y. Jin, et al., *Radiother. Oncol.* **149**, 55–62 (2020)

X. Shi, et al., *Proc. Natl. Acad. Sci.* **119** (2022).

**Blood (tumor) vessels** (i.e., causing less damage), potentially preventing changes in tumor vasculature that could affect its response to treatment (e.g., through better immune cells infiltration);

C. W. Song, et al., *Int. J. Radiat. Oncol. Biol. Phys.* **117**, 701–704 (2023).

## Metabolic hibernation

CL Limoli and MC Vozenin *Annual review of Cancer Biology.* **7**:1-21 (2023).

## Three main reasons to test C-ions

### 1. Test of the current mechanistic models at high-LET;

U. A. Weber, E. Scifoni, M. Durante, FLASH radiotherapy with carbon ion beams. *Med. Phys.* **49**, 1974–1992 (2022).


### 2. Clinical implementation in C-ion therapy;

M. Durante, J. Debus, J. S. Loeffler, Physics and biomedical challenges of cancer therapy with accelerated heavy ions. *Nat. Rev. Phys.* **3**, 777–790 (2021).

### 3. If the sparing effect survives at high-LET, possibility of using very heavy ions (such as $^{20}\text{Ne}$ or $^{40}\text{Ar}$ ) in therapy, and idea originally pursued by Cornelius Tobias at the Lawrence Berkeley Laboratory.

J. R. Castro, et al., Treatment of cancer with heavy charged particles. *Int. J. Radiat. Oncol. Biol. Phys.* **8**, 2191–2198 (1982).

C. A. Tobias, Failla Memorial lecture. The future of heavy-ion science in biology and medicine. *Radiat. Res.* **103**, 1–33 (1985).



- $5 \times 10^8$  carbon ions  
per synchrotron cycle (SPILL)

-7.5 Gy at 1 cm depth in water (entrance  
channel).

-Extraction of the whole spill within **100  
to 200 milliseconds** resulting in ultra-  
high dose rates of: **70 Gy/s**

The conventional irradiations  
took 12 seconds with a corresponding  
dose rate of  
**0.6 Gy/s.**





> Int J Radiat Oncol Biol Phys. 2022 Mar 15;112(4):1012-1022. doi: 10.1016/j.ijrobp.2021.11.020.  
Epub 2021 Nov 20.

## Ultra-High Dose Rate (FLASH) Carbon Ion Irradiation: Dosimetry and First Cell Experiments

Walter Tinganelli <sup>1</sup>, Olga Sokol <sup>1</sup>, Martina Quartieri <sup>1</sup>, Anggraeni Puspitasari <sup>1</sup>, Ivana Dokic <sup>2</sup>,  
Amir Abdollahi <sup>2</sup>, Marco Durante <sup>3</sup>, Thomas Haberer <sup>4</sup>, Jürgen Debus <sup>5</sup>, Daria Boscolo <sup>1</sup>,  
Bernd Voss <sup>1</sup>, Stephan Brons <sup>4</sup>, Christoph Schuy <sup>4</sup>, Felix Horst <sup>1</sup>, Ulrich Weber <sup>1</sup>



# FLASH Dose Rate Helium Ion Beams: First In Vitro Investigations

Tessonier et al. 2021



# First Human Cell Experiments With FLASH Carbon Ions

Mutsumi Tashiro<sup>1</sup>, Yukari Yoshida<sup>2</sup>, Takahiro Oike<sup>2,3</sup>, Masao Nakao<sup>2</sup>, Ken Yusa<sup>2</sup>, Yuka Hirota<sup>3</sup>, Tatsuya Ohno<sup>2,3</sup>







Test shot on radiochromic film before moving the mouse into the beam



**Data NOT  
PUBLISHED**

GSI SIS18  
FAIR-phase-0:  
12C-ions: 240 MeV/n  
**Plateau 10 Gy**  
FLASH local dose rate:  
➤ **>100 Gy/s**  
➤  $\sim 5 \times 10^9$  ions per spill  
Conventional dose rate:  
 $\sim 10$  Gy/min  
LET:  
**15 keV/micrometers**

CT imaging







Courtesy of M. Moustafa, DKFZ


# LM8 osteosarcoma in C3H mice

FLASH with carbon ions: Tumor control, normal tissue sparing, and distal metastasis in a mouse osteosarcoma model



Walter Tinganelli <sup>a</sup> · Ulli Weber <sup>a</sup> · Anggraini Puspitasari <sup>a</sup> · Palma Simoniello <sup>b</sup> · Amir Abdollahi <sup>c</sup> · Julius Oppermann <sup>a</sup>  
 Christoph Schuy <sup>a</sup> · Felix Horst <sup>a</sup> · Alexander Helm <sup>a</sup> · Claudia Fournier <sup>a</sup> · Marco Durante <sup>a,d</sup> [Show less](#)



## Beam application with 3D Range Modulators: Single-energy Irradiation



Simenov et al. J.Med. Phys. 2020



INTERNATIONAL JOURNAL OF  
**RADIATION ONCOLOGY • BIOLOGY • PHYSICS** ASTRO

BIOLOGY OR PHYSICS CONTRIBUTION · Articles in Press, November 26, 2024 · Open Access

### FLASH Bragg-Peak Irradiation With a Therapeutic Carbon Ion Beam: First In Vivo Results




Walter Tinganeli, PhD · Anggraeini Puspitasari-Kokko, MD, PhD<sup>†</sup> · Olga Sokal, PhD<sup>\*</sup> · Alexander Helm, PhD<sup>\*</sup> · Palma Simoniello, PhD<sup>‡</sup> · Christoph Schuy, PhD<sup>\*</sup> · Sylvie Lerchl, PhD<sup>\*</sup> · Denise Eckert, PhD<sup>\*</sup> · Julius Oppermann, MSc<sup>\*</sup> · Anna Rehm, PhD<sup>§</sup> · Stefan Janssen, PhD<sup>§</sup> · Denise Engel, PhD<sup>||</sup> · Ralf Moeller, PhD<sup>||,§§</sup> · Rossana Romano, MSc<sup>†</sup> · Felix Horst, PhD<sup>¶,¶¶</sup> · Daria Boscolo, PhD<sup>\*</sup> · Claudia Fournier, PhD<sup>\*</sup> · Marco Durante, PhD<sup>Ⓢ,Ⓣ,††</sup> · Uli Weber, PhD<sup>\*,††</sup> Show less



# Collagen deposition

Tinganelli et al. under revision

INTERNATIONAL JOURNAL OF  
RADIATION ONCOLOGY • BIOLOGY • PHYSICS




Grade	Description	Control	SHAM-IR	UHDR	CDR
0	No damage	5 (100%)	10 (100%)	3 (21%)	
1	Skin peeling and redness			11 (79%)	14 (93%)
2	Small wounds				1 (7%)

Table 1: Total and relative (in brackets) numbers of animals exhibiting skin damage in Control, Sham irradiated (SHAM-IR), Ultra high dose rate (UHDR), and Conventional dose rate (CDR) experimental groups.





# Combined treatments: Immune Checkpoint Inhibitors (ICI)


Monoclonal antibodies => **anti CTLA-4** and/or **anti PD-L1** or **PD-1**.




*Kooshkaki et al. 2020*





## Circulating Tumor Cells Neutrophil Extracellular Traps




*Coloured scanning electron micrograph showing stimulated neutrophil with NETs and trapped Shigella bacteria. © Max Planck Institute for Infection Biology*



**Data NOT  
PUBLISHED**






- Control No Drug
- Control CPI
- ▲ Conventional no Drug
- ▼ Conventional CPI
- ◆ FLASH no Drug
- FLASH CPI





# Circulating Tumor Cells and Neutrophil Extracellular traps

**Data NOT PUBLISHED**











Universitätsklinikum Erlangen



Courtesy of L. Munoz, Universitätsklinikum Erlangen

# Immune cell infiltration (7 days after radiation)

**Data NOT  
PUBLISHED**



- HIGH-LET correlates with a predicted substantial lowering of several conditions connected with the onset of the FLASH effect, according to the oxygen depletion model (ODM) (e.g., oxygen depletion, oxygen depletion pathway)

- **Oxygen depletion**
- **Intertrack recombination** returns a negative contribution to the oxygen depletion pathway;

Is there a role for FLASH in particle radiotherapy?  
Yes, FLASH has a role in particle therapy!

- **FLASH effects** are observed in vitro and in vivo.
- **FLASH is particularly effective** at high LET are necessary for the FLASH effect.
- In addition to the FLASH effect, the suppression of lung metastases may be a unique feature of particle beams, but needs to be investigated more in detail.
- Preliminary studies suggest no difference between conventional and FLASH dose rate in activating the immune system.

# Acknowledgments



**A. Puspitasari, A. Helm, P. Simoniello, C. Schuy, D. Boscolo, S. Lerchl, D. Eckert, A. Rehm, S. Janssen, D. Engel, R. Moeller, R. Romano, L. Munoz, U. Gaipl, C. Reichardt, S. Hui, C. Fournier, M. Durante**

## Special Thanks


**Uli Weber =Physics setup**



Dr. Olga  
Sokol  
Senior  
Scientist

Julius  
Oppermann

Dennis  
Fritsche



Reema  
Chowdhury

Tamara  
Vitacchio

Malte  
Benje



TECHNISCHE  
UNIVERSITÄT  
DARMSTADT



## ANNEX SLIDES

...but there is also a dose dependence as well

Authors correlate the magnitude of the FLASH effect (normal tissue sparing) as a function of the delivered dose.

FLASH modifying factor:  $FMF = D_{CONV} / D_{UHDR} |_{\text{isoeffect}}$

Up to 10 Gy => no FLASH effect or little effect for (single shot) irradiations (all data)

From 10 Gy to 20 Gy => up to 20% of the effect (mouse gut data)

Around 30 Gy => circa 30% sparing effect (mammalian skin-reaction data)

Conclusion: «The magnitude of normal tissue sparing by FLASH increases with dose and is dependent on the irradiated tissue»

Böhlen T.T., Germond J.-F., Bourhis J., Vozenin M.-C., Ozsahin E.M., Bochud F., et al. Normal Tissue Sparing by FLASH as a Function of Single-Fraction Dose: A Quantitative Analysis. *Int J Radiat Oncol*. 2022 doi: 10.1016/j.ijrobp.2022.05.038.


# Reinventing Radiobiology in the Light of FLASH Radiotherapy

Charles L. Limoli<sup>1</sup> and Marie-Catherine Vozenin<sup>2</sup>

<sup>1</sup>Department of Radiation Oncology, University of California, Irvine, California, USA; email: climoli@uci.edu

<sup>2</sup>Laboratory of Radiation Oncology, Radiation Oncology Service and Oncology Department, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland

## Low Toxicity on Normal tissues



...and in Human with Proton FLASH:

FAST-01: The first-in-human study investigates the use of ultrahigh dose rate proton FLASH therapy

Single-fraction treatment of painful bone metastases (12 metastatic sites) in the extremities in a routine clinical setting. Sample size 10 patients (27-81 years)

Dose rate of  $\geq 40$  Gy per second; Enrollment on November 3, 2020;

Results:

**Complete-partial pain relief** following FLASH was seen in 8 of 12 sites (7 of the 10 subjects) for an **overall response rate of 66.7%**.


E.C.Daugherty et al. FAST-01: Results of the First-in-Human Study of Proton FLASH Radiotherapy. 114(3)S4, 2022



**Mouse lung**  
Favaudon et al. (2014)  
Fouillade et al. (2020)

**Mouse gut**  
Levy et al. (2020)  
Velalopoulou et al. (2021)  
M.M. Kim et al. (2021)

**Human hematopoiesis**  
Chabi et al. (2021)



**Mouse brain**

Montay-Gruel et al. (2017)  
Montay-Gruel et al. (2018)  
Montay-Gruel et al. (2019)  
Simmons et al. (2019)  
Allen et al. (2020)  
Montay-Gruel et al. (2020)  
Alaghand et al. (2020)

**Mouse skin**

Field & Bewley (1974)  
Inada et al. (1980)  
Hendry et al. (1982)  
Soto et al. (2020)  
Cunningham et al. (2021)  
Velalopoulou et al. (2021)  
Sorensen et al. (2022)




Figure 1


Normal tissue sparing by FLASH radiotherapy. FLASH radiotherapy provides a unique opportunity to dose escalate while minimizing normal tissue toxicities throughout a variety of normal tissue beds. Reduced normal tissue complications have been found in nearly all normal tissues examined to date, using a variety of preclinical models. Figure adapted from images created with Biorender.com.

# From photon to particle therapy: The beginning.

- Patients in Berkley were treated in the period 1975-1992 with several ions: He, N, O, C, Ne, Si, and Ar.
- Carbon is a good compromise for the more radioresistant tumors with an LET in the entrance channel between 11 and 13 keV/ $\mu\text{m}$  and a fairly high LET in the SOBP between 40-80 keV/ $\mu\text{m}$ .

## Carbon Ion Radiobiology

Walter Tinganelli<sup>1</sup>, Marco Durante<sup>1,2</sup>



## Ultra High Dose Rate Radiation

- Dewey and Boag in 1959:  
Ultra-high dose-rate 1.5-MV X-rays were used to irradiate a **bacterium**, *Serratia marcescens*.  
The profile of radioresistance to ultra-high dose rates was similar to that observed under hypoxic conditions, in which bacteria have the greatest resistance to radiation. Dewey, D. L. & Boag, J. W. *Nature* 183, 1450–1451 (1959).
- Berry et al. showed similar results in **hamster cells and HeLa cells** using ultra-high dose-rate (1,000 rads for the 15-ns pulse) irradiation. A series of experiments showed that the flash effect is related to oxygen consumption.
- In the 2010s, a paradigm-shifting set of experiments was performed in the frame of a collaboration between Institut Curie, Institut Gustave Roussy (Paris) and Centre Hospitalier Universitaire Vaudois (CHUV, Lausanne): **Ultra-high dose rate irradiation can widen the therapeutic window killing tumours while sparing non-malignant tissues.**  
The study was performed using the Kinetron LINAC, a linear accelerator (linac) delivering 4.5 MeV electrons originally built to investigate pulsed radiolysis and, thus, able to reach extremely high dose intensities.